Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Blends · Dosing reference

BPC-157 + TB-500 Blend dosage

What the human evidence does and does not show, how long studies ran, and the arithmetic for working with vials.

Not approved — research use onlyCPreclinical researchNone established
Full research pageCycle-length evidenceComparePrefer Amiravo on Google
Regulatory status
Not approved — research use only
Human amounts
None established in humans
Route studied
—
Frequency
Not established
Half-life
Not established
Evidence grade
Grade C · Preclinical research
Vial sizes on the market
10 mg · 20 mg
Other forms seen
—

What BPC-157 + TB-500 Blend is

A combination of two synthetic peptides, BPC-157 and TB-500, studied together in preclinical models of tissue repair and cell migration.

This entry does not propose a mechanism for the mixture, because no mechanistic study of the two peptides acting together was identified 9,12. What follows describes the components separately, each of which has its own page. Components BPC-157 ( /library/bpc-157 ) is a pentadecapeptide described as corresponding to a partial sequence of a protein in human gastric juice; reviews report effects in rodent soft-tissue… How it works →

Key evidence

  • Bicer et al., Jt Dis Relat Surg · 2026 · Rats (Achilles tendon transection and repair, 32 male Sprague-Dawley animals)
    Single-agent groups showed improved histopathological parameters versus control, with a significant biomechanical advantage only for TB-500; the combined group showed no additional effect over either agent alone. 9
  • Lee & Padgett, Altern Ther Health Med · 2021 · Humans (16 private-clinic patients with knee pain, 4 of whom received both peptides)
    Three of the four patients who received BPC-157 with thymosin beta-4 were recorded as improved and one as not improved; the design does not permit any inference about the combination. 10
  • Tewari et al., Am J Sports Med · 2026 · Literature (animal and human studies of six marketed peptides)
    Reported that roughly two-thirds of publications were preclinical, that human studies were few and mostly uncontrolled, and that claimed musculoskeletal effects remain unsubstantiated by current human trials. 4
All studies on the research page

What the human evidence shows

No approved or established human dose

We searched PubMed and ClinicalTrials.gov and found no human studies that administered BPC-157 + TB-500 Blend. The research described on its page is from cells or animals, and animal amounts do not translate to people.

How long did human studies run?

No human study durations are recorded for BPC-157 + TB-500 Blend.

Cycle-length evidence for BPC-157 + TB-500 Blend

BPC-157 + TB-500 Blend draw calculator

Pick the vial strength and the water added, enter an amount, and see the concentration, the units to draw and how many draws the vial holds. Arithmetic only.

1 · Vial strength
sizes on the market
2 · Water added
3 · Amount per draw
4 · Syringe
Your mix
10 mg + 2 mL water = 5 mg/mL
10 units holds 0.5 mg (500 mcg)
Draw toEnter an amount in step 3
0102030405060708090100
U-100 syringe · 100 units = 1 mL

Computed from your inputs. Not a dose or a recommendation.

Compare water volumes for this vialShow

More water = lower concentration = a larger, easier-to-measure draw. Tap a row to use it.

Watermg/mLDraw
0.5 mL20—
1 mL10—
1.5 mL6.667—
2 mL5—
2.5 mL4—
3 mL3.333—
5 mL2—

Supplies and handling

  • Lyophilized vial
    Sealed vial with the freeze-dried cake. Check the label, lot and the certificate of analysis before opening.
  • Sterile diluent
    The diluent named on the product documentation. Bacteriostatic water contains benzyl alcohol; sterile water does not.
  • Graduated syringes
    Sized to the volume being measured. U-100 insulin syringes are graduated in units where 100 units = 1 mL.
  • Alcohol prep pads
    For wiping vial stoppers before each puncture.
  • Nitrile gloves
    Clean gloves for aseptic handling.
  • Sharps container
    Puncture-resistant container for used needles.
Step-by-step reconstitution guideStorage and transport accessories

Storage

General research-context handling only, and there is an added consideration for a multi-component vial: the two components are separate molecules with separate stability and solubility behaviour, and no published stability data for them combined in one container were identified. Defer to the supplier's own stability and handling documentation for the specific lot. No preparation or administration instructions are given on this page.

  • Lyophilized (unmixed) vials: typically stored cold and dry, away from light, as the documentation directs. Many are stable longer frozen.
  • Reconstituted vials: typically refrigerated (about 2–8 °C), protected from light and not frozen.
  • Bacteriostatic water contains benzyl alcohol, which inhibits bacterial growth in multi-use vials; sterile water has no preservative.

Handling mistakes and troubleshooting

Added the wrong volume of diluent
The concentration changes, not the amount of compound in the vial. Recalculate with the volume actually added and relabel the vial.
Shook the vial and it foamed
Let it settle in the refrigerator. Foam is a sign of agitation; some peptides aggregate when shaken. Note it on the label.
The solution is cloudy or has particles
Do not use it. Cloudiness can indicate incomplete dissolution, contamination or degradation. Record the lot and contact the supplier with the certificate of analysis.
The powder cake looks melted or shrunken before reconstitution
This can indicate the vial was exposed to heat or moisture. Record the lot and condition on arrival.
Liquid sprayed back when the needle was removed
Pressure built up in the vial. Withdraw a small volume of air while adding diluent to keep pressure neutral.

Regulatory status

Status
Neither component is approved by the FDA for any indication, and no approved product combining them exists 5,6. BPC-157 is named by WADA as an example of a non-approved substance prohibited at all times, and thymosin beta-4 and its derivatives including TB-500 are listed as prohibited growth factors 7. Neither BPC-157 nor TB-500 appears on FDA's May 14, 2026 list of bulk drug substances nominated for compounding under section 503A, in any of its three categories 8.
United States (FDA)
No FDA-approved application exists for BPC-157, for TB-500, or for any product combining them, and a DailyMed name search for BPC-157 returned no drug label 5,6. Neither substance appears on FDA's May 14, 2026 503A bulk drug substances list in category 1, 2 or 3 8. A 2026 analysis of Pharmacy Compounding Advisory Committee recommendations discusses the compounded-peptide category to which these products belong 6.
Sport (WADA)
The WADA 2026 Prohibited List names BPC-157 in section S0, Non-Approved Substances, which prohibits at all times any pharmacological substance not addressed by a later section and with no current approval by any governmental regulatory health authority for human therapeutic use, and introduces its examples with "including but not limited to" 7. Section S2.3, Growth Factors and Growth Factor Modulators, lists thymosin-beta-4 and its derivatives, naming TB-500, and is likewise introduced with "including, but not limited to" 7. Both components of this blend are therefore named, directly or as a derivative, and the class wording means that a substance's absence from the list would not amount to permission 7. Analytical methods for detecting N-acetylated LKKTETQ, the active ingredient of TB-500, in plasma have been published 14.

Status varies by country and changes over time. How we describe regulatory status.

BPC-157 + TB-500 Blend compared with related compounds

CompoundStatusEvidenceHuman amountsHalf-life
BPC-157 + TB-500 BlendNot approved — research use onlyCNone established—
BPC-157Not approved — research use onlyCNone established—
Thymosin beta-4InvestigationalBTrial dosesNot reported numerically in the sources
TB-500Not approved — research use onlyCNone established—
CJC-1295 (no DAC) + Ipamorelin BlendNot approved — research use only—None established—
CJC-1295 (no DAC) + GHRP-6 BlendNot approved — research use only—None established—

Frequently asked questions

What doses of BPC-157 + TB-500 Blend have been studied in humans?
None that establish an amount. BPC-157 + TB-500 Blend is not approved anywhere and we found no human studies that administered it. Amiravo does not publish community or vendor figures.
Is there an established BPC-157 + TB-500 Blend cycle length?
No. We found no human studies that report treatment duration for BPC-157 + TB-500 Blend.
How much bacteriostatic water should be added to a BPC-157 + TB-500 Blend vial?
There is no compound-specific volume. The diluent volume only sets the concentration: concentration = mass in the vial ÷ volume added (for example, 10 mg in 2 mL gives 5 mg/mL). The calculator on this page shows the arithmetic for any combination.
How many units is a given amount on an insulin syringe?
On a U-100 syringe, 100 units = 1 mL. Units for an amount = amount ÷ (concentration per unit). The calculator converts any amount you enter at the concentration you choose; a unit is a volume mark, not an amount of compound.
Is BPC-157 + TB-500 Blend FDA-approved?
Not approved — research use only. Neither component is approved by the FDA for any indication, and no approved product combining them exists 5,6. BPC-157 is named by WADA as an example of a non-approved substance prohibited at all times, and thymosin beta-4 and its derivatives including TB-500 are listed as prohibited growth factors 7. Neither BPC-157 nor TB-500 appears on FDA's May 14, 2026 list of bulk drug substances nominated for compounding under section 503A, in any of its three categories 8.

References

  1. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing Cell Tissue Res. 2019
  2. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review Pharmaceuticals (Basel). 2025
  3. Thymosin beta-4: a multi-functional regenerative peptide. Basic properties and clinical applications Expert Opin Biol Ther. 2012
  4. Peptide Supplements and Their Therapeutic Applications in Sports Medicine Am J Sports Med. 2026
  5. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance Sports Med. 2026
  6. Synthetic Peptides in Pharmacy Compounding: Analysis of PCAC Recommendations and Industry Safety Standards Int J Pharm Compd. 2026
  7. World Anti-Doping Code International Standard: Prohibited List 2026 WADA. 2026
  8. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (updated May 14, 2026) FDA. 2026
  9. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study Jt Dis Relat Surg. 2026
  10. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain Altern Ther Health Med. 2021
  11. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians Am J Sports Med. 2026
  12. Dangers of Injectable Peptides and Other Unregulated "Biohacking" Drugs Mo Med. 2026
  13. Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications JBJS Rev. 2026
  14. Doping control analysis of seven bioactive peptides in horse plasma by liquid chromatography-mass spectrometry Anal Bioanal Chem. 2013

Last reviewed October 22, 2026 by the Amiravo editorial team. Editorial policy · Report an error